SCHEMBL4898256

SCHEMBL4898256

Cc1cc(CNCC(C)C)cnc1-c1ccc(C(=O)Nc2ccccc2N)cc1

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 20/20 0.66
KCNH2 Q12809 4/20 0.53
HDAC2 Q92769 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5801668 0.91 HDAC1 (0.62) HDAC1KCNH2HDAC2
SCHEMBL3608357 0.90 HDAC1 (0.66) HDAC1KCNH2HDAC2
SCHEMBL4897259 0.89 HDAC1 (0.69) HDAC1KCNH2HDAC2
SCHEMBL4899357 0.89 HDAC1 (0.70) HDAC1KCNH2HDAC2
SCHEMBL4887537 0.88 HDAC1 (0.67) HDAC1KCNH2HDAC2
SCHEMBL2074823 0.87 HDAC1 (0.68) HDAC1KCNH2
SCHEMBL4897235 0.87 HDAC1 (0.71) HDAC1KCNH2HDAC2
SCHEMBL4898946 0.87 HDAC1 (0.66) HDAC1KCNH2HDAC2
SCHEMBL4890516 0.86 HDAC1 (0.67) HDAC1KCNH2HDAC2
SCHEMBL4892787 0.86 HDAC1 (0.65) HDAC1KCNH2HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119451-A1 Novel Benzamide Derivatives ASTRAZENECA AB (SE) 2008-05-22 US claimed
WO-2006077387-A2 NOVEL BENZAMIDE DERIVATIVES ASTRAZENECA AB (SE) 2006-07-27 WO claimed
US-20080119451-A1 Novel Benzamide Derivatives ASTRAZENECA AB (SE) 2008-05-22 US disclosed
WO-2006077387-A2 NOVEL BENZAMIDE DERIVATIVES ASTRAZENECA AB (SE) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119451-A1 Novel Benzamide Derivatives HDAC1, HDAC11, HDAC2 HDAC1 1/4885KCNH2 1230/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.